Pneumagen is developing a glycan targeted intranasally delivered therapy for the pan-viral, universal treatment of infectious diseases of the respiratory tract
Latest news
19 Jan, 2022
Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)
10 Nov, 2021
Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections
08 Mar, 2021
Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection
Meet the team
Douglas Thomson
Chief Executive Officer
Dr David Howat
Development Director
Thomas Engelen
Non-executive Chairman
Professor Garry Taylor
Director and Chairman of the Scientific Advisory Board
Mark R. Bamforth
Non-executive Director